Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SENP5 | Q96HI0 | 16/20 | 0.50 |
| ▸ | SENP2 | Q9HC62 | 16/20 | 0.50 |
| ▸ | SENP1 | Q9P0U3 | 16/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | CMA1 | P23946 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL999164 | 0.89 | CMA1 (0.44) | SENP5SENP2SENP1CMA1NPC1 | |
| SCHEMBL1000593 | 0.82 | CMA1 (0.54) | SENP5SENP2SENP1PTGS2USP2 | |
| SCHEMBL4139599 | 0.74 | PRSS12 (0.45) | CMA1NPC1 | |
| SCHEMBL4132747 | 0.74 | PRSS12 (0.47) | NPC1RAB9A | |
| SCHEMBL999165 | 0.69 | CMA1 (0.60) | SENP5SENP2SENP1CMA1NPC1 | |
| SCHEMBL942502 | 0.69 | CMA1 (0.63) | CMA1NPC1RAB9A | |
| SCHEMBL10021087 | 0.68 | PTGS2 (0.72) | SENP5SENP2SENP1PTGS2USP2 | |
| SCHEMBL10260556 | 0.67 | CMA1 (0.50) | SENP5SENP2SENP1CMA1NPC1 | |
| SCHEMBL1001213 | 0.67 | CMA1 (0.68) | CMA1NPC1RAB9A | |
| SCHEMBL14470506 | 0.66 | IMPDH2 (0.73) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222431-B2 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-17 | — | — | US | claimed |
| JP-2011500682-A | — | — | 2011-01-06 | — | — | JP | claimed |
| EP-2211867-A1 | PROCESS FOR SYNTHESIZING PHOSPHONIC AND PHOSPHINIC ACID COMPOUNDS | Janssen Pharmaceutica N.V. (BE) | 2010-08-04 | — | — | EP | claimed |
| US-20090124801-A1 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-14 | — | — | US | claimed |
| WO-2009051746-A1 | PROCESS FOR SYNTHESIZING PHOSPHONIC AND PHOSPHINIC ACID COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-23 | — | — | WO | claimed |
| US-20120259130-A1 | PROCESS FOR SYNTHESIZING PHOSPHONIC AND PHOSPHINIC ACID COMPOUNDS | ANZALONE LUIGI (US) | 2012-10-11 | — | — | US | disclosed |
| US-8222431-B2 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-17 | — | — | US | disclosed |
| EP-2211867-A1 | PROCESS FOR SYNTHESIZING PHOSPHONIC AND PHOSPHINIC ACID COMPOUNDS | Janssen Pharmaceutica N.V. (BE) | 2010-08-04 | — | — | EP | disclosed |
| US-20090124801-A1 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-14 | — | — | US | disclosed |
| WO-2009051746-A1 | PROCESS FOR SYNTHESIZING PHOSPHONIC AND PHOSPHINIC ACID COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124801-A1 | Process for synthesizing phosphonic and phosphinic acid compounds | CMA1, PPA1, CPN1 | SENP5 337/4885SENP2 314/4885SENP1 396/4885 |
| US-20120259130-A1 | PROCESS FOR SYNTHESIZING PHOSPHONIC AND PHOSPHINIC ACID COMPOUNDS | CMA1, PPA1, CPN1 | SENP5 337/4885SENP2 314/4885SENP1 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.